N-(3-chloro-4-(4-ethylpiperazin-1-yl)phenyl)-3-cyclopentylpropanamide | 1012788-60-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N-(3-chloro-4-(4-ethylpiperazin-1-yl)phenyl)-3-cyclopentylpropanamide
• 英文别名: N-[3-chloro-4-(4-ethylpiperazin-1-yl)phenyl]-3-cyclopentylpropanamide
• CAS: 1012788-60-1
• 化学式: C₂₀H₃₀ClN₃O
• 分子量: 363.931
• InChiKey: IWSOFJPLHFSLJW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  35.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-chloro-4-(4-ethylpiperazin-1-yl)aniline 、 3-环戊基丙酰氯 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 N-(3-chloro-4-(4-ethylpiperazin-1-yl)phenyl)-3-cyclopentylpropanamide
  参考文献：
  名称：

  Synthesis and SAR of selective muscarinic acetylcholine receptor subtype 1 (M1 mAChR) antagonists

  摘要：

  This Letter describes the synthesis and SAR, developed through an iterative analogue library approach, of a novel series of selective M1 mAChR antagonists for the potential treatment of Parkinson's disease, dystonia, and other movement disorders. Compounds in this series possess M1 antagonist IC50S in the 441 nM-19 mu M range with 8- to >340-fold functional selectivity versus rM2-rM5. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.12.051

文献信息

• Therapeutic compositions for diabetic symmetrical polyneuropathy
  申请人：Fernyhough Paul

  公开号：US10307428B2

  公开（公告）日：2019-06-04

  Compositions for therapy of a diabetic symmetrical polyneuropathy a subject in need thereof, the compositions comprising: an effective amount of a muscarinic acetylcholine receptor antagonist exemplified by pirenzepine, telenzepine, atropine, or derivatives thereof or salts thereof or analogs thereof or derivatives thereof, and a pharmacologically acceptable carrier. The composition may be injectable or alternatively, may be applied topically or alternatively, may be delivered orally. A suitable topical composition may comprise a lotion, a cream, a gel, or a viscous fluid. The muscarinic acetylcholine receptor antagonist may be a muscarinic acetylcholine receptor antagonist salt or a muscarinic acetylcholine receptor antagonist derivative or a muscarinic acetylcholine receptor antagonist analog.

  用于治疗糖尿病对称性多发性神经病变的组合物，该组合物包括：有效量的毒蕈碱乙酰胆碱受体拮抗剂，例如哌仑西平、替氮平、阿托品或其衍生物或其盐或其类似物或其衍生物，以及药理学上可接受的载体。该组合物可以注射，也可以局部使用，还可以口服。合适的局部组合物可包括乳液、膏霜、凝胶或粘稠液体。毒蕈碱乙酰胆碱受体拮抗剂可以是毒蕈碱乙酰胆碱受体拮抗剂盐或毒蕈碱乙酰胆碱受体拮抗剂衍生物或毒蕈碱乙酰胆碱受体拮抗剂类似物。
• THERAPEUTIC COMPOSITIONS FOR DIABETIC SYMMETRICAL POLYNEUROPATHY
  申请人：Fernyhough Paul

  公开号：US20130267506A1

  公开（公告）日：2013-10-10

  Compositions for therapy of a diabetic symmetrical polyneuropathy a subject in need thereof, the compositions comprising: an effective amount of a muscarinic acetylcholine receptor antagonist exemplified by pirenzepine, telenzepine, atropine, or derivatives thereof or salts thereof or analogs thereof or derivatives thereof, and a pharmacologically acceptable carrier. The composition may be injectable or alternatively, may be applied topically or alternatively, may be delivered orally. A suitable topical composition may comprise a lotion, a cream, a gel, or a viscous fluid. The muscarinic acetylcholine receptor antagonist may be a muscarinic acetylcholine receptor antagonist salt or a muscarinic acetylcholine receptor antagonist derivative or a muscarinic acetylcholine receptor antagonist analog.
• TREATMENTS FOR DIABETIC SYMMETRICAL POLYNEUROPATHY
  申请人：University of Manitoba

  公开号：US20190046540A1

  公开（公告）日：2019-02-14

  Treatments for therapy of a diabetic symmetrical polyneuropathy a subject in need thereof. The treatments includes administration of compositions comprising: an effective amount of a muscarinic acetylcholine receptor antagonist exemplified by pirenzepine, telenzepine, atropine, or derivatives thereof or salts thereof or analogs thereof or derivatives thereof, and a pharmacologically acceptable carrier. The composition may be injectable or alternatively, may be applied topically or alternatively, may be delivered orally. A suitable topical composition may comprise a lotion, a cream, a gel, or a viscous fluid. The muscarinic acetylcholine receptor antagonist may be a muscarinic acetylcholine receptor antagonist salt or a muscarinic acetylcholine receptor antagonist derivative or a muscarinic acetylcholine receptor antagonist analog.
• [EN] THERAPEUTIC COMPOSITIONS FOR DIABETIC SYMMETRICAL POLYNEUROPATHY<br/>[FR] COMPOSITIONS THÉRAPEUTIQUES POUR UNE POLYNEUROPATHIE DIABÉTIQUE SYMÉTRIQUE
  申请人：UNIV MANITOBA

  公开号：WO2012055018A1

  公开（公告）日：2012-05-03

  Compositions for therapy of a diabetic symmetrical polyneuropathy a subject in need thereof, the compositions comprising: an effective amount of a muscarinic acetylcholine receptor antagonist exemplified by pirenzepine, telenzepine, atropine, or derivatives thereof or salts thereof or analogs thereof or derivatives thereof, and a pharmacologically acceptable carrier. The composition may be injectable or alternatively, may be applied topically or alternatively, may be delivered orally. A suitable topical composition may comprise a lotion, a cream, a gel, or a viscous fluid. The muscarinic acetylcholine receptor antagonist may be a muscarinic acetylcholine receptor antagonist salt or a muscarinic acetylcholine receptor antagonist derivative or a muscarinic acetylcholine receptor antagonist analog.
• Synthesis and SAR of selective muscarinic acetylcholine receptor subtype 1 (M1 mAChR) antagonists
  作者：L. Michelle Lewis、Douglas Sheffler、Richard Williams、Thomas M. Bridges、J. Phillip Kennedy、J.T. Brogan、Matthew J. Mulder、Lyndsey Williams、Natalia T. Nalywajko、Colleen M. Niswender、Charles D. Weaver、P. Jeffrey Conn、Craig W. Lindsley

  DOI：10.1016/j.bmcl.2007.12.051

  日期：2008.2

  This Letter describes the synthesis and SAR, developed through an iterative analogue library approach, of a novel series of selective M1 mAChR antagonists for the potential treatment of Parkinson's disease, dystonia, and other movement disorders. Compounds in this series possess M1 antagonist IC50S in the 441 nM-19 mu M range with 8- to >340-fold functional selectivity versus rM2-rM5. (C) 2007 Elsevier Ltd. All rights reserved.